hrp0082p1-d3-162 | Growth (2) | ESPE2014

Infliximab Improves Growth in Paediatric Crohn’s disease Only if Commenced Early in Puberty or Prior to the Onset of Puberty

Gangadharan Arundoss , Metcalf Joanna , Giri Dinesh , Irving Sharon , Auth Marcus , Venkatesh Krishnappa , Krishnamurthy Balaji , Blair Joanne C , Didi Mohammed

Background: Crohn’s disease is a relapsing systemic inflammatory disorder with inflammatory bowel disease (IBD) due to up-regulation of pro-inflammatory cytokines including TNFα. More than 80% of newly diagnosed children present with growth failure Paediatric gastroenterology units in the UK submit data to the UK IBD database which can be accessed when required. One aim of current treatment protocols is to promote growth. Studies on the use of anti-TNFα antibodi...

hrp0082p2-d3-493 | Endocrine Oncology | ESPE2014

Role of Metformin in the Treatment of Hypothalamic Obesity

Gangadharan Arundoss , Didi Mohammed , Pizer Barry , Howell Lisa , Hayden James , Mallucci Conor , Pettorini Benedetta , Blair Joanne C

Background: Disruption of homeostatic functioning of the hypothalamic centres results in hyperphagia, autonomic imbalance, reduction of energy expenditure, and hyperinsulinemia. A syndrome of rapid, unrelenting weight gain is often observed in patients with structural lesions of the hypothalamus. Hypothalamic obesity syndrome (HOS) is often refractory to standard dietary and lifestyle interventions. It has been reported that metformin induces anorectic effects via an increase ...